GEAN — Genetic Analysis As Income Statement
0.000.00%
Last trade - 00:00
- NOK20.63m
- NOK9.78m
- NOK14.15m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | — | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.29 | 5.78 | 6.8 | 11.2 | 14.1 |
Cost of Revenue | |||||
Gross Profit | 5.56 | 4.75 | 5.52 | 7.26 | 9.72 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14 | 27.7 | 35.7 | 39.3 | 38 |
Operating Profit | -6.75 | -22 | -28.9 | -28.2 | -23.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.94 | -22.1 | -29 | -28.3 | -23.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.94 | -22.1 | -29 | -28.3 | -23.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.94 | -22.1 | -29 | -28.3 | -23.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.94 | -22.1 | -29 | -28.3 | -23.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.1 | -0.2 | -1.15 | -1.13 | -0.624 |
Dividends per Share |